Previous 10 | Next 10 |
2024-04-15 09:15:00 ET Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (NASDAQ: VRTX) announced it would purchase Alpine Immune Sciences (NASDAQ: ALPN) for $4.9 billion in cash in a deal that's set to close before the end of this quarte...
2024-04-13 05:29:00 ET The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (NASDAQ: ALPN) from Vertex Pharmaceuticals (NASDAQ: VRTX) . Vertex recently offered Alpine Immune Sciences $65 per share, or about $...
2024-04-12 05:08:54 ET Summary Vertex Pharmaceuticals is the world's only provider of gene-based therapy for cystic fibrosis, with a $10 billion revenue business. The acquisition of Alpine Immune Sciences adds another therapy to Vertex's pipeline, potentially increasing the compan...
NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alpine Immune Sciences, Inc. (NAS...
2024-04-11 16:48:36 ET Summary Vertex Pharmaceuticals Incorporated is acquiring Alpine Immune Sciences, Inc. for $4.9 billion in cash to obtain the use of povetacicept for IgAN and other kidney disorders. Positive results of povetacicept for treatment of patients with IgAN were fi...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) fell 26.7% to $0.717 on volume of 293,193,103 shares PROSHARES TRUST (SQQQ) fell 4.6% to $10.4 on volume of 158,399,098 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 6.4% to $3.21 on volume o...
2024-04-11 15:23:48 ET Summary Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion, gaining access to povetacicept, a potential treatment for IgA nephropathy and up to seven additional indications. Povetacicept has shown promising results in reducing protei...
2024-04-11 12:55:33 ET More on Mid-day movers & stocks. Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript Veru Inc. (VERU) Q1 2024 Earnings Call Transcript Veru gets Na...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is one today's most active stocks by volume. So far today, approximately 21.37M shares of Alpine Immune Sciences, Inc. have been exchanged, as compared to an average 30-day volume of 1.63M shares. Alpine Immune Sciences, Inc., a clinical-stage biopha...
2024-04-11 10:04:28 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Well...
News, Short Squeeze, Breakout and More Instantly...
Alpine Immune Sciences Inc. Company Name:
ALPN Stock Symbol:
NASDAQ Market:
Alpine Immune Sciences Inc. Website:
FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades...
2024-05-19 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceutic...